Coronado Biosciences Announces Phase 2 Study Evaluating TSO in Ulcerative Colitis
December 21, 2012 07:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., Dec. 21, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...